[
  {
    "ts": "2025-11-24T12:30:00+00:00",
    "headline": "Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership",
    "summary": "TORONTO & CAMBRIDGE, Mass., November 24, 2025--Versant Ventures today announced the launch of Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for a range of serious diseases. The company has secured more than $70 million in committed funding, including a collaboration with Biogen Inc. that will provide $50 million in upfront capital, as well as an equity commitment from Versant.",
    "url": "https://finance.yahoo.com/news/versant-ventures-announces-launch-dayra-123000662.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "648ceb2d-9224-35ee-90a2-56754248f4ed",
      "content": {
        "id": "648ceb2d-9224-35ee-90a2-56754248f4ed",
        "contentType": "STORY",
        "title": "Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership",
        "description": "",
        "summary": "TORONTO & CAMBRIDGE, Mass., November 24, 2025--Versant Ventures today announced the launch of Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for a range of serious diseases. The company has secured more than $70 million in committed funding, including a collaboration with Biogen Inc. that will provide $50 million in upfront capital, as well as an equity commitment from Versant.",
        "pubDate": "2025-11-24T12:30:00Z",
        "displayTime": "2025-11-24T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/c4bf08255a6be0c52262ae88c10f2073",
          "originalWidth": 4000,
          "originalHeight": 1066,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6a9jqdFtk2NiwoSRkJqBkQ--~B/aD0xMDY2O3c9NDAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/c4bf08255a6be0c52262ae88c10f2073.cf.webp",
              "width": 4000,
              "height": 1066,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uD9qlXiLiuv_2MRvO14SvQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c4bf08255a6be0c52262ae88c10f2073.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/versant-ventures-announces-launch-dayra-123000662.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/versant-ventures-announces-launch-dayra-123000662.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-24T12:30:00+00:00",
    "headline": "Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions",
    "summary": "Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and incorporating an additional clinically validated modality into its expanding immunology capabilities CAMBRIDGE, Mass. and TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Dayra Therapeutics today announced a research collaboration to discover and develop or",
    "url": "https://finance.yahoo.com/news/biogen-dayra-therapeutics-announce-research-123000391.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "278b46b0-a7c5-3a93-9df4-3b41ede5feab",
      "content": {
        "id": "278b46b0-a7c5-3a93-9df4-3b41ede5feab",
        "contentType": "STORY",
        "title": "Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions",
        "description": "",
        "summary": "Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and incorporating an additional clinically validated modality into its expanding immunology capabilities CAMBRIDGE, Mass. and TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Dayra Therapeutics today announced a research collaboration to discover and develop or",
        "pubDate": "2025-11-24T12:30:00Z",
        "displayTime": "2025-11-24T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-dayra-therapeutics-announce-research-123000391.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-dayra-therapeutics-announce-research-123000391.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-24T12:17:09+00:00",
    "headline": "Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps",
    "summary": "Novo Nordisk reported Monday that a Ozempic pill failed to slow the progression of Alzheimer's in two big studies. Novo dived, Eli Lilly fell. Biogen rose.",
    "url": "https://www.investors.com/news/novo-nordisk-dives-ozempic-fails-slow-alzheimers-eli-lilly-biogen/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "a51cd60d-fe17-396c-bf06-7516a239f75c",
      "content": {
        "id": "a51cd60d-fe17-396c-bf06-7516a239f75c",
        "contentType": "STORY",
        "title": "Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps",
        "description": "",
        "summary": "Novo Nordisk reported Monday that a Ozempic pill failed to slow the progression of Alzheimer's in two big studies. Novo dived, Eli Lilly fell. Biogen rose.",
        "pubDate": "2025-11-24T12:17:09Z",
        "displayTime": "2025-11-24T12:17:09Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/a51cd60d-fe17-396c-bf06-7516a239f75c/novo-nordisk-dives-as-ozempic.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/817e6030ee2ae5f493a5abec2e2fbfba",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7obXGavYr8kgk3K.Mtzb2w--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/817e6030ee2ae5f493a5abec2e2fbfba.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jzjG937xziJt0639IwSv.A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/817e6030ee2ae5f493a5abec2e2fbfba.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/novo-nordisk-dives-ozempic-fails-slow-alzheimers-eli-lilly-biogen/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]